LifeVantage Corporation LFVN R2K
Company Overview
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre and pro-biotics and skin and hair care products internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; LifeVantage Daily Wellness, a dietary supplement to strengthen immune health; LifeVantage Rise AM and Reset PM System that provides the body with the right nutrients; LifeVantage D3+, a dietary supplement that provides vitamin D3 and K2, magnesium, calcium, and other trace minerals to support a balanced immune system, strong bones, and cardiovascular health; PhysIQ Fat Burn to support weight management; PhysIQ Prebiotic is a dietary supplement designed to support the good bacteria in the gut and a healthy microbiome; MindBody GLP-1 System, a dietary supplement that combines two products, MB Core and MB Enhance, which are designed to support weight management and wellness by activating GLP-1 naturally and balancing signals along the gut-brain axis; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. It also provides anti-aging skin care products, such as liquid collagen, facial cleansers, eye cream, moisturizing cream, sunscreen, perfecting lotions, and hand creams, as well as shampoos, nourishing conditioners, and scalp serums under the TrueScience brand name. It sells its products through its website and network of independent consultants. LifeVantage Corporation is based in Lehi, Utah.
Why Investors Should Care
Generates a return on equity of 17.1%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 27.3%.
Revenue has grown at a 13.5% CAGR over the past five years.
Trades at a P/E of 13.8, below the sector median of 20.9.
Carries low leverage with a debt-to-equity ratio of 0.31.
Offers a dividend yield of 2.21%.
Recent Developments
- Jun 2025 Revenue of $228.53M (+14.2% YoY); net profit $9.80M.
- Trailing 12 Months Year-on-year growth — revenue -25.2%, earnings -58.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 13.5%, profit CAGR -3.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 13.48% |
| 1 Year: | -25.20% |
Compounded Profit Growth
| 5 Years: | -3.22% |
| 1 Year: | -58.50% |
Stock Price Performance
| 1 Year: | -48.58% |
| 6 Months: | -2.92% |
| 3 Months: | +49.63% |
| 1 Month: | -34.67% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Golden Cross10d ago
- RSI (14)43.39 · Neutral
P/E of 13.78 is below the sector median of 20.95 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 27.3%.
- Compounding revenue at 13.5% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -3.2% CAGR over 5 years.
- Trading 56.1% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Consumer Defensive).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LFVN LifeVantage Corporation R2K | 6.20 | 13.78 | $78.22M | 2.21% | 27.27% | 17.08% | 13.48% | -3.22% |
| 2 | WMT Walmart Inc. SPX | 113.70 | 40.04 | $904.83B | 0.89% | 18.21% | 24.13% | 5.27% | 23.30% |
| 3 | COST Costco Wholesale Corporation NDXSPX | 921.75 | 46.46 | $408.78B | 0.60% | 25.96% | 29.15% | 8.16% | 11.45% |
| 4 | KO The Coca-Cola Company SPX | 83.08 | 26.13 | $357.45B | 2.57% | 16.47% | 43.37% | 2.86% | 4.46% |
| 5 | PG The Procter & Gamble Company SPX | 146.08 | 21.36 | $340.16B | 2.85% | 22.93% | 31.11% | 0.36% | 1.66% |
| 6 | PM Philip Morris International Inc. SPX | 175.95 | 24.78 | $274.23B | 3.19% | 34.03% | -113.55% | -1.69% | 3.57% |
| 7 | PEP PepsiCo, Inc. NDXSPX | 135.45 | 21.23 | $185.13B | 4.10% | 15.41% | 43.88% | 4.93% | 2.11% |
| 8 | MO Altria Group, Inc. SPX | 70.16 | 14.65 | $117.16B | 5.89% | 38.27% | - | 1.24% | -1.89% |
| 9 | MNST Monster Beverage Corporation NDXSPX | 98.00 | 47.34 | $95.84B | 0.00% | 28.33% | 26.65% | 13.03% | 14.82% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 49.13M | 49.48M | 50.56M | 54.03M | 55.61M | 58.17M | 56.01M | 56.17M | 56.23M | 61.24M | 56.08M | 59.37M | 54.83M | 59.01M | 51.57M | 54.78M | 53.22M | 52.19M | 50.00M | 50.94M | 51.77M | 53.66M | 53.74M | 51.36M | 51.62M | 48.24M | 47.21M | 67.76M | 58.44M | 47.56M | 48.93M | 43.72M |
| Gross Profit | 38.38M | 44.15M | 46.45M | 43.63M | 46.06M | 41.45M | 36.77M | 41.75M | 40.39M | 40.37M | 41.64M | 45.96M | 46.41M | 48.37M | 46.74M | 46.46M | 47.04M | 51.01M | 46.98M | 49.92M | 45.43M | 48.82M | 42.75M | 44.99M | 43.79M | 42.51M | 40.35M | 41.61M | 41.83M | 41.90M | 43.12M | 41.18M | 40.56M | 38.07M | 37.72M | 54.57M | 47.33M | 37.82M | 36.21M | 34.54M |
| Operating Income | 2.67M | 3.03M | 3.63M | - | 1.99M | 700.00K | 223.00K | - | 1.40M | 2.33M | 2.30M | - | 1.32M | 581.00K | 2.24M | - | 2.58M | 3.65M | 3.03M | - | 3.50M | 5.45M | 2.09M | - | 4.61M | -358.00K | 1.82M | - | 1.29M | -1.23M | 1.60M | 749.00K | -1.26M | 1.93M | 2.57M | 3.43M | 4.05M | 2.27M | 487.00K | 1.68M |
| Net Income | 1.07M | 1.60M | 1.00M | 2.44M | 1.18M | 283.00K | 61.00K | 84.00K | 817.00K | 317.00K | 1.64M | 2.99M | 911.00K | 829.00K | 1.78M | 3.91M | 1.76M | 4.30M | 1.66M | 3.82M | 2.45M | 3.81M | 1.72M | 4.91M | 3.32M | 79.00K | 1.14M | -1.42M | 610.00K | -1.06M | 1.02M | 629.00K | -656.00K | 1.66M | 1.83M | 2.55M | 3.47M | 2.15M | 276.00K | 1.36M |
| Diluted EPS | 0.08 | 0.11 | 0.07 | 0.17 | 0.08 | 0.02 | 0.00 | 0.01 | 0.06 | 0.02 | 0.12 | 0.21 | 0.06 | 0.06 | 0.12 | 0.26 | 0.12 | 0.30 | 0.11 | 0.26 | 0.17 | 0.26 | 0.12 | 0.35 | 0.25 | 0.01 | 0.09 | -0.11 | 0.05 | -0.08 | 0.08 | 0.05 | -0.05 | 0.13 | 0.14 | 0.19 | 0.26 | 0.17 | 0.02 | 0.11 |
| R&D Expense | 200.00K | - | - | - | 300.00K | 300.00K | 200.00K | - | 300.00K | 300.00K | 300.00K | - | 400.00K | 500.00K | 100.00K | - | 200.00K | 300.00K | 200.00K | - | 200.00K | 200.00K | 200.00K | - | 200.00K | 200.00K | 100.00K | - | 100.00K | 200.00K | 200.00K | 200.00K | 100.00K | 200.00K | 300.00K | 200.00K | 400.00K | 300.00K | 200.00K | 200.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.92M | 126.18M | 208.18M | 213.97M | 190.34M | 206.54M | 199.49M | 203.20M | 225.96M | 232.91M | 220.18M | 206.36M | 213.40M | 200.16M | 228.53M |
| Gross Profit | 33.00M | 108.13M | 171.53M | 180.77M | 162.33M | 172.61M | 166.03M | 168.36M | 187.99M | 194.95M | 181.99M | 168.26M | 170.01M | 158.72M | 183.67M |
| Operating Income | 3.70M | 21.46M | 12.07M | 19.45M | 13.90M | 13.41M | 4.45M | 10.32M | 9.81M | 15.47M | 17.61M | 7.58M | 4.26M | 4.33M | 12.20M |
| Net Income | -50.79M | 12.47M | 7.61M | 11.38M | 7.12M | 6.11M | 1.61M | 5.76M | 7.43M | 11.55M | 12.89M | 3.12M | 2.54M | 2.94M | 9.80M |
| Diluted EPS | -0.69 | 0.11 | 0.06 | 0.71 | 0.50 | 0.42 | 0.11 | 0.41 | 0.50 | 0.79 | 0.90 | 0.24 | 0.20 | 0.23 | 0.75 |
| R&D Expense | 509.00K | 1.40M | 2.90M | 2.00M | 2.40M | 1.00M | 1.10M | 1.20M | 1.10M | 900.00K | 700.00K | 700.00K | 600.00K | 700.00K | 1.40M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jul 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 12.50M | 44.53M | 55.48M | 54.00M | 39.78M | 50.85M | 45.25M | 51.14M | - | 55.27M | 58.88M | 78.73M | 70.71M | 66.12M | 60.30M | 71.96M |
| Total Equity | -16.18M | -20.81M | 28.28M | 33.95M | 2.33M | 1.81M | 10.65M | 14.53M | 21.95M | 21.94M | 27.20M | 33.25M | 36.81M | 31.52M | 34.65M | 25.99M | 34.64M |
| Cash & Equivalents | 1.64M | 6.37M | 24.65M | 26.30M | 20.39M | 13.90M | 7.88M | 11.46M | 16.65M | - | 18.82M | 22.14M | 23.17M | 20.19M | 21.61M | 16.89M | 20.20M |
| Long Term Debt | - | - | - | 0 | 25.07M | 8.53M | 7.41M | 5.44M | 3.41M | - | 0 | - | - | - | - | - | - |
| Total Liabilities | - | 33.31M | 16.25M | 21.54M | 50.01M | 36.46M | 40.21M | 30.72M | 29.20M | - | 28.07M | 25.62M | 41.92M | 39.19M | 31.47M | 34.31M | 37.32M |
| Current Liabilities | - | 13.38M | 16.03M | 20.57M | 22.70M | 25.86M | 30.63M | 23.36M | 23.80M | - | 26.20M | 25.02M | 25.20M | 25.73M | 19.61M | 22.31M | 27.22M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 4.68M | 19.39M | 10.66M | 12.11M | 13.22M | 6.04M | 6.60M | 13.26M | 17.79M | 18.33M | 16.27M | 7.96M | 6.83M | 12.20M | 11.88M |
| Investing Cash Flow | -89.00K | -1.90M | -5.08M | -2.25M | -1.16M | -562.00K | -1.05M | -4.65M | -4.51M | -2.68M | -3.73M | -1.53M | -3.06M | -2.25M | -1.37M |
| Financing Cash Flow | 169.00K | 746.00K | -4.02M | -15.80M | -18.45M | -11.70M | -1.96M | -3.50M | -11.12M | -12.42M | -11.45M | -8.95M | -2.36M | -14.42M | -7.60M |
| Capital Expenditure | -122.00K | -2.19M | -5.08M | -1.90M | -1.16M | -562.00K | -1.05M | -4.65M | -2.51M | -2.68M | -3.74M | -1.53M | -3.07M | -2.25M | -1.37M |
| Free Cash Flow | 4.56M | 17.20M | 5.58M | 10.21M | 12.06M | 5.47M | 5.54M | 8.61M | 15.28M | 15.64M | 12.53M | 6.43M | 3.76M | 9.95M | 10.51M |
| Share Buybacks | 0 | 976.00K | 7.12M | 46.17M | 9.85M | 0 | 0 | 1.50M | 4.66M | 5.41M | 11.93M | 8.83M | 822.00K | 6.43M | 3.15M |
| Dividends Paid | - | - | - | - | - | - | - | - | - | 0 | 0 | 378.00K | 1.59M | 6.94M | 2.07M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 84.8% | 85.7% | 82.4% | 84.5% | 85.3% | 83.6% | 83.2% | 82.9% | 83.2% | 83.7% | 82.7% | 81.5% | 79.7% | 79.3% | 80.4% |
| Operating Margin % | 9.5% | 17.0% | 5.8% | 9.1% | 7.3% | 6.5% | 2.2% | 5.1% | 4.3% | 6.6% | 8.0% | 3.7% | 2.0% | 2.2% | 5.3% |
| Net Margin % | -130.5% | 9.9% | 3.7% | 5.3% | 3.7% | 3.0% | 0.8% | 2.8% | 3.3% | 5.0% | 5.9% | 1.5% | 1.2% | 1.5% | 4.3% |
| ROE % | 244.1% | 44.1% | 22.4% | 487.9% | 394.5% | 57.3% | 11.1% | 26.2% | 27.3% | 34.7% | 35.0% | 9.9% | 7.3% | 11.3% | 28.3% |
| ROCE % | -419.8% | 75.3% | 34.6% | 62.1% | 99.8% | 66.3% | 20.3% | 37.8% | 33.8% | 45.7% | 32.9% | 16.8% | 9.2% | 11.4% | 27.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Capital Management Corporation | 19.36% | 2.44M | $15.16M |
| 2 | Renaissance Technologies, LLC | 6.88% | 867.70K | $5.39M |
| 3 | Blackrock Inc. | 6.10% | 769.70K | $4.78M |
| 4 | Vanguard Capital Management LLC | 3.40% | 429.42K | $2.67M |
| 5 | Dimensional Fund Advisors LP | 2.19% | 276.20K | $1.72M |
| 6 | Geode Capital Management, LLC | 2.07% | 261.19K | $1.62M |
| 7 | Envestnet Asset Management Inc. | 1.74% | 219.16K | $1.36M |
| 8 | Goldman Sachs Group Inc | 1.47% | 185.11K | $1.15M |
| 9 | State Street Corporation | 1.32% | 167.14K | $1.04M |
| 10 | AQR Capital Management, LLC | 1.24% | 156.10K | $969.36K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LFVN
LifeVantage Corporation (NASDAQ:LFVN) Pays A US$0.05 Dividend In Just Three Days - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQWXZ2ZHNoVW9sREdaVkNQaUk1SXNhYzBxaHM0cnJXdldwanRtVmk5SGxIaEJsY0szVVBGbmU5aTdVZklvRXlYd3dQMEh3U2FJN3ZFeHBib1dGRl96VWtrVEJBdXZqelByRjE4T0Z2REpDRTlpa1lKd0pWQ3UyaEtTa0YxY1g1NEFSWFV5QW…
(LFVN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxPN2J6NHhwYUFWd0ZZLWttTUlsNkhOd0hrcGJGeXBsTWtqX0laamJSUUZBdktrdzNTdnlmM2w0al9CdkxJTDV2MFI5YVBtZDl3Y3d1SjRTVlZnVmt5N2xDZzg0U2VCeHBVMjlrRFhRVDR4dGxHcno5N1htTDNuNFJsUWc4LVFTV29fc0FVLW…
LifeVantage Corp (LFVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE1XMkRqX08zZ2NoQ0d0ZzRNcXc5MEo5eTgzRkdLcFRjVTZEamQ0andQMkItd2UwTmkwQWlHOS1xLUwwYXZ6MlZoYkowVUtoMFItZnY1VHU4cHJKSUdXUm1wRk5ac2YzaWhhczRJdHZmWWo?oc=5" target="_blank">LifeVantage Corp…
LFVN Stock Price and Chart — NASDAQ:LFVN - TradingView
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTFBhZXdnNWdrQ3R2WFNsSjZPWVpBV05fNFFobGc5MHEtdmdGcFdBazluVGlUano2N0cwVS1OOVdzdEhUdUxzOUR6MW5DcVVWT05FVXBwUmtOclEwUWxH?oc=5" target="_blank">LFVN Stock Price and Chart — NASDAQ:LFVN</a…
$LFVN stock is up 13% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPb0hNQ25QTG5PSEp5Rk82ZUFSSHFPMFJiMVQ2WlBpZlRfR0taYVJLb3R6a1lmVUIxaFJkTi15V0RHdjJsajdMMFZtalpxdFQ2ZElGSzZ2WGxxZDR5ME1zVlJseS1XX2dzTTJqS0hOU2FiamliSWhTaV9NbGFLYmtwRTN2NEF0QXo1OUFlZz…
LifeVantage will pay shareholders more cash this June 15 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxOQU9PcERzUEdQckRyb291OF85aWw0dmE0OERpeU12LXd4LW8wX0JUby1zNlhmVFVEN1p1a1FTZnJZZkFMZE9Yc2tXbVFvV0xjZTJBTU1Obnd3TlAybjltcDloc2I0eXI0ZWhvYnZJR3dhWVhZdjQ4TEVKMzhvbW9tR3dlb0dMUHUxQzNnOT…
LFVN — Frequently Asked Questions
What is the current share price of LifeVantage Corporation (LFVN)?
As of 2026-07-14 21:23 PDT, LifeVantage Corporation (LFVN) trades at $6.20 on NasdaqCM. Its 52-week range is $3.99 to $14.13.
What is the market capitalisation of LFVN?
LifeVantage Corporation (LFVN) has a market capitalisation of $78.22M on NasdaqCM.
What is the P/E ratio of LFVN?
LFVN trades at a trailing price-to-earnings (P/E) ratio of 13.78. The industry average P/E is 20.95. Its price-to-book (P/B) ratio is 3.42.
Does LFVN pay a dividend?
LifeVantage Corporation (LFVN) currently offers a dividend yield of 2.21%.
What is the return on equity (ROE) of LFVN?
LFVN has a return on equity (ROE) of 17.08%. Its return on capital employed (ROCE) is 27.27%.
Is LFVN a good stock to buy?
This page provides a data-driven analysis of LifeVantage Corporation (LFVN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.